Physicochemical, biological, functional and toxicological characterization of the European follow-on glatiramer acetate product as compared with Copaxone

Weinstein, 2015, Non-Biological Complex Drugs. The Science and the Regulatory Landscape, 107 Campos-García, 2017, Design of a strong cation exchange methodology for the evaluation of charge heterogeneity in glatiramer acetate, J. Pharm. Biomed. Anal., 132, 133, 10.1016/j.jpba.2016.10.002 Public Assessment Report Cohen, 2015, Equivalence of Generic glatiramer Acetate in Multiple Sclerosis: a randomized clinical trial, JAMA Neurol., 72, 1433, 10.1001/jamaneurol.2015.2154 Annovazzi P., Bertolott A., Morra V.B. et al., A comprehensive review on Copemyl. Neurol Ther. DOI 10.1007/540120-017-0079.3 Selmaj, 2017, Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results, Mult. Scler., 23, 1909, 10.1177/1352458516688956 Fekete, 2015, Method development for the separation of monoclonal antibody charge variants in cation exchange chromatography, part I: salt gradient approach, J. Pharm. Biomed. Anal., 102, 33, 10.1016/j.jpba.2014.08.035 Ruggeri, 2016, AFM-based single molecule techniques: unraveling the amyloid pathogenic species, Curr. Pharm. Des., 22, 3950, 10.2174/1381612822666160518141911 La Gatta, 2010, A complete hyaluronan hydrodynamic characterization using a size exclusion chromatography-triple detector array system during in vitro enzymatic degradation, Anal. Biochem., 404, 21, 10.1016/j.ab.2010.04.014 Uetrecht, 2010, Ion mobility mass spectrometry of proteins and protein assemblies, Chem. Soc. Rev., 39, 1633, 10.1039/B914002F Shvartsburg, 2015, 2014 ASMS fall workshop: ion mobility mass spectrometry, J. Am. Soc. Mass Spectrom., 26, 1051, 10.1007/s13361-015-1155-5 Hasson, 2016, Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition, J. Neuroimmunol., 290, 84, 10.1016/j.jneuroim.2015.11.020 Grossman, 2017, Compositional differences between Copaxone and Glatopa are reflected in altered immunomodulation ex vivo in a mouse model, Ann. N. Y. Acad. Sci., 10.1111/nyas.13547 Komlosh, 2016, Similarities and differences in properties of glatiramer acetate (Copaxone®, Teva) versus Polimunol (Synthon) using standard and emerging technologies, Eur. J. Neurol., 23, 205 Komlosh, 2015, Comparison of physicochemical, biological, and genomic characteristics of differently manufactured glatiramoids to ensure MS patient safety Kolitz, 2015, Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids, Sci. Rep., 5, 10.1038/srep10191 Towfic, 2014, Comparing the biological impact of glatiramer acetate with the biological impact of a generic, PLoS One, 9, 10.1371/journal.pone.0083757 Aharoni, 2014, Immunomodulation neuroprotection and remyelination - the fundamental therapeutic effects of glatiramer acetate: a critical review, J. Autoimmun., 54, 81, 10.1016/j.jaut.2014.05.005 Federal Register Fromen, 2016, Nanoparticle surface charge impacts distribution, uptake and lymph node trafficking by pulmonary antigen-presenting cells, Nanomedicine, 12, 677, 10.1016/j.nano.2015.11.002 Molotsky, 2015, Characterization of Copaxone by atomic force microscopy (AFM) and dynamic light scattering (DLS) Johnson, 2007, Adjusting batch effects in microarray expression data using empirical Bayes methods, Biostatistics, 8, 118, 10.1093/biostatistics/kxj037 Leek, 2013, vol. 3 Smyth, 2004, Linear models and empirical bayes methods for assessing differential expression in microarray experiments, Stat. Appl. Genet. Mol. Biol., 3, 10.2202/1544-6115.1027 Subramanian, 2005, Gene set enrichment analysis: a knowledgebased approach for interpreting genome-wide expression profiles, Proc. Natl. Acad. Sci., 102, 15545, 10.1073/pnas.0506580102 Bhattacharjee, 2010, Role of surface charge and oxidative stress in cytotoxicity of organic monolayer-coated silicon nanoparticles towards macrophage NR8383 cells, Part Fibre Toxicol., 7, 25, 10.1186/1743-8977-7-25 Foged, 2005, Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model, Int. J. Pharm., 298, 315, 10.1016/j.ijpharm.2005.03.035 Frohlich, 2012, The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles, Int. J. Nanomedicine, 7, 5577, 10.2147/IJN.S36111 Ramot, 2012, Comparative long-term preclinical safety evaluation of two glatiramoid compounds (glatiramer acetate, COPAXONE(R), and TV-5010, protiramer) in rats and monkeys, Toxicol. Pathol., 40, 40, 10.1177/0192623311424169 Varkony, 2009, The glatiramoid class of immunomodulator drugs, Expert. Opin. Pharmacother., 10, 657, 10.1517/14656560902802877 Ramirez, 2015, Rates of adverse events and multiple sclerosis relapses before and after introduction of a purported generic glatiramer acetate in Mexico: results from a large patient support program in Mexico, Value Health, 18, A877, 10.1016/j.jval.2015.09.050 Wolinsky, 2015, GLACIER: an open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis, Mult. Scler. Rel. Disord., 4, 370, 10.1016/j.msard.2015.06.005 Johnson, 1995, Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial, Neurology, 45, 1268, 10.1212/WNL.45.7.1268 Johnson, 1998, Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability, Neurology, 50, 701, 10.1212/WNL.50.3.701